Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Penederm acquisition

This article was originally published in The Tan Sheet

Executive Summary

For $205 mil. brings a pipeline of four products using Penederm's TopiCare liquid polymer topical drug delivery technology, the most advanced of which is an antifungal/steroid 501 cream (butenafine 1%/betamethasone .064%), which may treat skin fungal disorders in seven days. An NDA is slated for filing in the second half. In Phase III is a topical butenafine for nail fungus for which Penederm is partnering with Schering-Plough in the U.S. Earlier-stage products include a vitamin D analog for psoriasis in (Phase II) and an acne and photoaging vitamin D treatment (Phase I). SmithKline Beecham uses TopiCare in an OTC dry skin product sold in Europe, and Penederm has a licensing deal with Warner-Lambert for an OTC dry skin therapy in Canada. With the purchase, Mylan also gains three Rx Penederm products that could be possible switch candidates: Ativa for acne, Mentax antifungal and Acticin for scabies...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel